Patents by Inventor Hq Han
Hq Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932677Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: GrantFiled: February 28, 2022Date of Patent: March 19, 2024Assignee: AliveGen Inc.Inventors: Hq Han, Xiaolan Zhou
-
Publication number: 20230391863Abstract: This invention disclosure provides novel bifunctional antagonistic polypeptides comprising at least one TNF-? binding domain and at least one Activin-binding domain, which are highly capable of sequestering TNF-? and Activin or Activin-related ligand in parallel. Also provided are pharmaceutical compositions of such bifunctional polypeptide antagonists and their uses to treat various complex disease conditions, whose pathogenesis involve the activation of both TNF-?-mediated NF-?B signaling pathway and Activin-mediated Smad2/3 signaling pathway.Type: ApplicationFiled: October 22, 2021Publication date: December 7, 2023Inventors: HQ Han, Xiaolan Zhou
-
Publication number: 20230391880Abstract: This invention disclosure provides novel bifunctional molecules comprising at least one RANKL binding molecule and at least one Activin or TGF-? binding molecule, which are capable of sequestering RANKL and Activin or TGF-? in parallel. Also provided are pharmaceutical compositions of such bifunctional antagonist molecules and their therapeutic uses to treat various bone disorders whose pathogenesis involves the activation of both RANKL-NF?B and Activin/TGF?-Smad2/3 signaling pathways, such as bone metastasis, bone loss in cancer, bone fragility in neuromuscular diseases, osteogenesis imperfecta, fracture, osteopenia and osteoporosis.Type: ApplicationFiled: November 5, 2021Publication date: December 7, 2023Inventors: HQ Han, Xiaolan Zhou
-
Publication number: 20230391892Abstract: This invention disclosure provides novel bifunctional antagonistic polypeptides comprising at least one TNF-? binding domain and at least one TGF-? binding domain, which are highly capable of sequestering TNF-? and TGF-? in parallel. Also provided are pharmaceutical compositions of such bifunctional polypeptide antagonists and their uses to treat various complex disease conditions, whose pathogenesis involve the activation of both TNF-?-mediated NF-?B signaling pathway and TGF-?-mediated Smad2/3 signaling pathway.Type: ApplicationFiled: October 22, 2021Publication date: December 7, 2023Inventors: HQ Han, Xiaolan Zhou
-
Publication number: 20220332783Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: ApplicationFiled: February 28, 2022Publication date: October 20, 2022Applicant: AliveGen Inc.Inventors: HQ Han, Xiaolan Zhou
-
METHODS FOR TREATING MUSCLE WASTING AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS
Publication number: 20220332791Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: ApplicationFiled: December 7, 2021Publication date: October 20, 2022Applicant: AliveGen Inc.Inventors: HQ HAN, Xiaolan ZHOU -
Patent number: 11292826Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: GrantFiled: June 8, 2020Date of Patent: April 5, 2022Assignee: Biogen MA Inc.Inventors: Hq Han, Xiaolan Zhou
-
Patent number: 10913782Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: GrantFiled: April 12, 2016Date of Patent: February 9, 2021Assignee: Biogen MA Inc.Inventors: Hq Han, Xiaolan Zhou
-
Publication number: 20200362009Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: ApplicationFiled: June 8, 2020Publication date: November 19, 2020Applicant: Biogen MA Inc.Inventors: HQ Han, Xiaolan Zhou
-
METHODS FOR TREATING MUSCLE WASTING AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS
Publication number: 20190330307Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: ApplicationFiled: October 19, 2017Publication date: October 31, 2019Applicant: BIOGEN MA INC.Inventors: HQ HAN, Xiaolan ZHOU -
Publication number: 20180148491Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: ApplicationFiled: April 12, 2016Publication date: May 31, 2018Applicant: AliveGen USA, Inc.Inventors: HQ Han, Xiaolan Zhou
-
Patent number: 8614292Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.Type: GrantFiled: July 25, 2011Date of Patent: December 24, 2013Assignee: Amgen Inc.Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20130230515Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: November 20, 2012Publication date: September 5, 2013Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Patent number: 8410043Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: GrantFiled: November 25, 2009Date of Patent: April 2, 2013Assignee: Atara Biotherapeutics, Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas C. Boone, Rohini Deshpande, Yue-Sheng Li, Hq Han
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Patent number: 8071538Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: August 23, 2010Date of Patent: December 6, 2011Inventors: Hq Han, Hosung Min, Thomas C. Boone
-
Patent number: 8067562Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.Type: GrantFiled: October 31, 2006Date of Patent: November 29, 2011Assignee: Amgen Inc.Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20110281796Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.Type: ApplicationFiled: July 25, 2011Publication date: November 17, 2011Applicant: Amgen Inc.Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20110183897Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Applicant: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 7928075Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: February 10, 2009Date of Patent: April 19, 2011Assignee: Amgen Inc.Inventors: Hq Han, Hosung Min, Thomas C. Boone